Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillermo Lopez

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Plos One|May 6, 2009
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expressionRafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, et al.
The Journal of Clinical Endocrinology and Metabolism|July 4, 2020
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell TreatmentNaomi Todd, Ross McNally, Abdelrahim Alqudah, et al.
The New England Journal of Medicine|August 21, 2009
Screening for epidermal growth factor receptor mutations in lung cancerRafael Rosell, Teresa Moran, Cristina Queralt, et al.
Nature|November 7, 2006
Resveratrol improves health and survival of mice on a high-calorie dietJoseph A Baur, Kevin J Pearson, Nathan L Price, et al.
Cell Reports|January 10, 2025
The adaptor protein Miro1 modulates horizontal transfer of mitochondria in mouse melanoma modelsJaromir Novak, Zuzana Nahacka, Gabriela L Oliveira, et al.
BMC Infectious Diseases|September 2, 2011
Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenzaRaquel Almansa, Andres Anton, Paula Ramirez, et al.
Critical Care (London, England)|September 16, 2010
Host adaptive immunity deficiency in severe pandemic influenzaJesus F Bermejo-Martin, Ignacio Martin-Loeches, Jordi Rello, et al.
Frontiers in Immunology|September 28, 2023
Rationale for combined therapies in severe-to-critical COVID-19 patientsAitor Gonzaga, Etelvina Andreu, Luis M Hernández-Blasco, et al.
Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Plos One|May 6, 2009
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expressionRafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, et al.
The Journal of Clinical Endocrinology and Metabolism|July 4, 2020
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell TreatmentNaomi Todd, Ross McNally, Abdelrahim Alqudah, et al.
The New England Journal of Medicine|August 21, 2009
Screening for epidermal growth factor receptor mutations in lung cancerRafael Rosell, Teresa Moran, Cristina Queralt, et al.
Nature|November 7, 2006
Resveratrol improves health and survival of mice on a high-calorie dietJoseph A Baur, Kevin J Pearson, Nathan L Price, et al.
Cell Reports|January 10, 2025
The adaptor protein Miro1 modulates horizontal transfer of mitochondria in mouse melanoma modelsJaromir Novak, Zuzana Nahacka, Gabriela L Oliveira, et al.
BMC Infectious Diseases|September 2, 2011
Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenzaRaquel Almansa, Andres Anton, Paula Ramirez, et al.
Critical Care (London, England)|September 16, 2010
Host adaptive immunity deficiency in severe pandemic influenzaJesus F Bermejo-Martin, Ignacio Martin-Loeches, Jordi Rello, et al.
Frontiers in Immunology|September 28, 2023
Rationale for combined therapies in severe-to-critical COVID-19 patientsAitor Gonzaga, Etelvina Andreu, Luis M Hernández-Blasco, et al.
Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Pageof 12